Building a bioscience business in Cheshire Dr John Ridden CEO and Co-Founder 26 th June 2014

Building a bioscience business in Cheshire Blueberry Therapeutics Blueberry - The company A small drug discovery and development company Projects through to clinical proof-of-concept, then license on for further development Portfolio based on the innovative use of nanotechnology to reformulate drugs and create NMEs Inflammation and infection focussed Current area of interest is dermatology

Building a bioscience business in Cheshire Blueberry Therapeutics Blueberry - The company Based here at BioHub 120m 2 lab space 30m 2 office space Fully Equipped 6 Staff Bioscience and clinical

Building a bioscience business in Cheshire Blueberry Therapeutics Blueberry technology Nanocin™ Nanoparticle based delivery platform Massively enhances drug delivery into cells and tissues

Building a bioscience business in Cheshire Blueberry Therapeutics Blueberry technology Nanoparticles <20nm in diameter First synthesised >80 years ago >30 years of safe clinical use Stable at room temperature for up to 5 years Well tolerated in the eye, ear, skin, gut and lung. Massively enhances drug delivery into cells and tissue. –Protein –Peptide, –DNA –RNA –Natural products –Small molecules Nanocin tm - enhanced topical delivery platform

Building a bioscience business in Cheshire Blueberry Therapeutics Blueberry technology Nanocin tm technology - a clinically safe polymer Already used in a range of over the counter and off the shelf human healthcare products Always as a biocide Products containing Nanocin include; inter-operative irrigation, pre- and post-surgery skin and mucous membrane disinfection, post-operative dressings, surgical and non-surgical wound dressings, surgical bath/hydrotherapy, chronic wounds like diabetic foot ulcer and burn wound management, routine antisepsis during minor incisions, catheterization, ‘scopy, first aid, surface disinfection, and linen disinfection Eye drops Wound dressing Wound care Hand wash Contact lens

Building a bioscience business in Cheshire Blueberry Therapeutics CTA/IND Drug resistant bacterial infection BB5000 Tinea Pedis BB2603 Peptide aptamer Inflammatory bowel disease BB0109 Peptide therapeutic Launch Skin care BB2300 Atopic dermatitis BB2702 Peptide therapeutic Onychomycosis BB0305 MARKET The Blueberry Portfolio 2014 Small molecule Acne treatment BB2312 Topical biologic PreclinicalClinical

Building a bioscience business in Cheshire Blueberry Therapeutics Building a bioscience business isn’t easy……

Building a bioscience business in Cheshire Blueberry Therapeutics The road ahead…

Building a bioscience business in Cheshire Blueberry Therapeutics …..requires careful navigation

Building a bioscience business in Cheshire Blueberry Therapeutics It’s about taking calculated risks

Building a bioscience business in Cheshire Blueberry Therapeutics With a solid team We operate using a contemporary business model Blueberry staff Scientific and clinical advisory board Partners Collaborators

Building a bioscience business in Cheshire Blueberry Therapeutics The Blueberry management team and advisors Team MemberBiography Dr Dave Cook (AstraZeneca)Drug discovery, safety and inflammation Dr Liam Good (RVC)Nanopolymers and Bacteriology Dr Maria Marlowe (Nottingham Bimolecular Centre)Nanopolymer formulations Dr Alex O’Neill (Leeds University)Bacterial resistance mechanisms Dr Wal WardEnzymology Dr Sudax Murdan (UCL)Fungal Infections Dr Mike DaviesDrug Development Blueberry have recruited an experienced advisory board ‘THE SCAB’ Working alongside our small but experienced team

Building a bioscience business in Cheshire Blueberry Therapeutics Blueberry partners Blueberry Therapeutics Weightmans PITCH&CO Technology Strategy Board Appleyard Lees Gary Burns Biocity/Biohub Bionow UKTI

Building a bioscience business in Cheshire Blueberry Therapeutics Blueberry collaborators Blueberry Therapeutics Manchester University Manchester University Newcastle University Liverpool University Liverpool University Leeds University Public Health England RVC SME UCL Pharma Sheffield University

Building a bioscience business in Cheshire Blueberry Therapeutics Protecting intellectual property Blueberry Patent & Intellectual Property Overview Lead compound IP assigned from AstraZeneca to Blueberry Therapeutics in return for 1st right to negotiate at PoC.  Candidate anti-inflammatory compounds in patent application phase  Exclusive license to an industry leading, clinically safe nanopolymer based delivery system  Patent applications for biologic approach to Bacterial Multi Drug Resistance  Patent application for fungal infection treatment  Exclusive license to 2 peptide aptamer screening platforms 

Building a bioscience business in Cheshire Blueberry Therapeutics And finally… After 3 years of being the leader of a Biotech business “ Experience is something you don’t get until just after you need it!”

Dr John Ridden Co-Founder / CEO Tel: Thank you